Search
for
Sort by
Research 30 of 1000+
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Dermatologic Adverse Events from Cancer Treatments
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Dermatological adverse events with taxane chemotherapy
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Clinical development and management of adverse events associated with FGFR inhibitors
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Art of prevention: The importance of dermatologic care when using aromatase inhibitors
- Dermatologic Care of the Transplant Patient
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Are Pediatric GLP ‐1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age‐Specific Patterns and Their Implications for Dermatologists
- Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome
- A one-year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients
- Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study